Capital International Ltd. CA Has $35.67 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY

Capital International Ltd. CA reduced its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 5.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 78,223 shares of the biopharmaceutical company’s stock after selling 4,577 shares during the quarter. Alnylam Pharmaceuticals accounts for approximately 1.3% of Capital International Ltd. CA’s holdings, making the stock its 18th biggest position. Capital International Ltd. CA’s holdings in Alnylam Pharmaceuticals were worth $35,670,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in ALNY. Root Financial Partners LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at $25,000. Salomon & Ludwin LLC bought a new stake in Alnylam Pharmaceuticals in the third quarter valued at about $27,000. Atlantic Union Bankshares Corp acquired a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $30,000. Ameriflex Group Inc. acquired a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth $32,000. Finally, ORG Partners LLC raised its position in shares of Alnylam Pharmaceuticals by 70.2% during the third quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 33 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 2,290 shares of the company’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $370.33, for a total transaction of $848,055.70. Following the sale, the executive vice president directly owned 21,264 shares of the company’s stock, valued at $7,874,697.12. This represents a 9.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Yvonne Greenstreet sold 9,577 shares of the business’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $362.86, for a total value of $3,475,110.22. Following the sale, the chief executive officer owned 78,411 shares in the company, valued at approximately $28,452,215.46. The trade was a 10.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 53,923 shares of company stock valued at $18,072,087 over the last quarter. 1.20% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $323.53 on Tuesday. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76. The firm’s 50-day simple moving average is $350.74 and its 200 day simple moving average is $413.17. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $205.87 and a fifty-two week high of $495.55. The stock has a market cap of $42.91 billion, a price-to-earnings ratio of 189.20 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The business had revenue of $1.10 billion during the quarter, compared to the consensus estimate of $1.16 billion. During the same period in the prior year, the company earned ($0.65) earnings per share. The business’s revenue was up 84.9% on a year-over-year basis. As a group, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ALNY. Stifel Nicolaus upped their target price on shares of Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Wells Fargo & Company decreased their price objective on shares of Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating for the company in a research report on Tuesday, January 20th. Royal Bank Of Canada lowered their price target on shares of Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating on the stock in a report on Tuesday, January 20th. Bank of America reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 12th. Finally, Leerink Partners decreased their price target on Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating on the stock in a research note on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $477.96.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.